Technical analysis of Alkermes plc (ALKS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Price Performance
| 1 month | -6.89% |
| 3 months | +2.40% |
| Year-to-date | +64.65% |
| 1 year | +65.30% |
| 3 years | +53.93% |
52-Week Range
| 52-week High | $55.67 |
| 52-week Low | $26.50 |
| Avg Volume (90d) | 2.0M |
Technical Indicators
| SMA 50 | $49.45 |
| SMA 200 | $38.31 |
| Beta | 0.39 |
| 30-day Volatility (annualised) | 23.3% |
| Price vs SMA 50 | -6.8% |
| Price vs SMA 200 | +20.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $30.70 | |
| 2025-11 | $29.58 | -3.6% |
| 2025-12 | $27.98 | -5.4% |
| 2026-01 | $33.89 | +21.1% |
| 2026-02 | $30.10 | -11.2% |
| 2026-03 | $35.36 | +17.5% |
| 2026-04 | $33.71 | -4.7% |
| 2026-05 | $42.19 | +25.2% |
| 2026-06 | $52.40 | +24.2% |
| 2026-07 | $48.99 | -6.5% |
| 2026-08 | $46.99 | -4.1% |
| 2026-09 | $46.07 | -2.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | $17M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.23 | $227M |
| 2026-09-15 | | |
Price
| Price | $46.07 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | IE |
Valuation Ratios
| P/E Ratio | 112.07 |
| Price / Book | 4.16 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.87 |
| Current Ratio | 2.30 |